While there is less evidence for their efficacy in humans against respiratory viruses, for which clinical trials have been limited to adenoviral infections [31], studies in mice have shown that adoptive therapy with CD8+ and/or CD4+ T cells can efficiently control respiratory infections, including in models of SARS-CoV-1 [32–34]. Here, CD8A is linked to respiratory tract infectious disorder.